Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.

We report the emergence of drug-resistant viral mutations in chronically HIV-infected individual undergoing structured treatment interruptions (STI). THe protease mutations K101E and K103N were detected at the end of the second or third STI. We concluded that the repeated abrupt termination and resumption of certain antiretroviral drug regimens during STI therapy may lead to the development of drug resistance in chronically HIV-infected individuals.

[1]  F. Brun-Vézinet,et al.  A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. , 1998, The New England journal of medicine.

[2]  J. Ioannidis,et al.  Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.

[3]  V. Calvez,et al.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. , 1999, AIDS.

[4]  M. Plana,et al.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. , 1999, AIDS.

[5]  R. Paredes,et al.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.

[6]  L. Bacheler,et al.  Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.

[7]  Rapid Communication: Efavirenz- and Adefovir Dipivoxil–Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response , 2000 .

[8]  G. M. Ortiz,et al.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.

[9]  L. Montaner.  Structured treatment interruptions to control HIV-1 and limit drug exposure. , 2001, Trends in immunology.

[10]  K. Hertogs,et al.  Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  V. Calvez,et al.  Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection , 2001, Journal of Virology.

[12]  G. M. Ortiz,et al.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[13]  Brendan Larder,et al.  Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy , 2001, Journal of Virology.

[14]  D. Montefiori,et al.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Clotet,et al.  Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions , 2002, AIDS.